← 產業報告目錄

AI in Oncology Market by Player Type (Integrated Suite), Application (Drug Discovery, De Novo Drug Design, Diagnosis, Precision Medicine, Genomic), Technology (CNN, NLP), Cancer Type (Lung), End User (Hospitals, Pharma), & Region - Global Forecast to 2030

出版商 MarketsandMarkets產業別 Healthcare & Life Sciences出版日期 2024-12-20頁數 581報告編號 HIT9231

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global AI in Oncology market is projected to reach USD 11.52 billion by 2030 from USD 2.45 billion in 2024, at a CAGR of 29.4% from 2024 to 2030. The market's growth is fuelled by the growing demand for cost-effective cancer treatments & solutions, streamlining of the drug discovery process, rapid digitization of healthcare records and patient data, the growing volume of cancer cases, and regulatory compliance requirements. In March 2024, the journal published by the American Cancer Society stated the following key points: • More than 80% of AI devices that are FDA-approved are used in cancer detection & diagnosis. These devices have applications in the following: pathology (19.7%), radiology (54.9), and radiation oncology (8.5%). • AI aided in decreasing the workload of radiologists in breast cancer screening by 30% and in comparison to healthcare professionals, AI maintained more accuracy. • AI combined with human evaluations improved cancer detection rates by 8% in various studies. • Precision medicine tools powered by AI contributed to the 33% decline in cancer mortality rates over the past 32 years by enabling better diagnoses, tailored treatments, and optimized clinical decision-making. However, integration with existing healthcare systems, data privacy, and security constraints pose a significant challenge within this market. “Machine learning held the largest share in technology type in the AI in oncology market in 2023.” The AI in oncology market is segmented based on technology into machine learning, natural language processing (NLP), context-aware processing and computing, computer vision, and image analysis (including optical character recognition). The machine learning segment held the largest market share in 2023. Further, the machine learning segment includes deep learning (including convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies. Among these, deep learning is the largest segment owing to its capability to analyze and process vast and complex datasets including medical images with improved efficiency. Within deep learning technologies such as CNNs are effective for image-based cancer detection, while RNNs and GANs are used to improve the temporal pattern analysis and data synthesis. Moreover, deep learning's scalability, adaptability and precision in analyzing and identifying the subtle patterns in cancer helped in improving the diagnosis, risk predictions and treatment optimization. “By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period.” By player type, the AI in oncology market is divided into niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers. The integrated suite/platform providers segment accounts for the largest and is projected to be the fastest-growing segment over the forecast year. “By player type, the integrated solution segment is the largest and is also expected to register the fastest growth over the forecast period.” The growth is attributed to the fact that these providers offer comprehensive end-to-end solutions to streamline workflows across all treatment sectors of cancer such as detection, diagnosis, monitoring, and treatment planning. Such platforms help to integrate technologies including NLP, computer vision, and machine learning resulting in better clinical decision-making and offering seamless data interoperability. Moreover, integrated suite/platform helps in decreasing the need for multiple vendors as they are unified systems due to their scalability and flexibility which results in cost effective solution. This holistic approach drives adoption and fuels rapid growth. “Asia Pacific is estimated to register the highest CAGR over the forecast period.” The AI in Oncology market is segmented mainly into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The AI in oncology market in Asia Pacific is projected to register at the highest CAGR rate during the forecast period. The growth of this region is due to the development of healthcare infrastructure, and government initiatives to modernize and digitalize the healthcare industry particularly due to rising cancer cases, growth in minimally invasive cancer treatments, and to increase in the survival rate of cancer patients. Countries such as Japan, China, and India are focusing on developing cost-effective solutions in cancer care emphasizing the importance of AI-driven data management to handle sensitive patient information and ensure compliance with regulatory mandates for healthcare data standardization. Various key players and startups in the countries are promoting AI use in cancer such as Niramai, a Bangalore-based health tech startup, developed Thermalytix, an AI-driven breast cancer screening solution. The technology uses non-invasive, radiation-free thermal imaging and machine learning algorithms to detect breast cancer at an earlier stage compared to traditional methods. The solution is designed for all ages and ensures privacy, portability, and high accuracy. It is available in over 30 cities across 200+ hospitals in India and is expanding globally to different countries, thereby, transforming preventive cancer care. Breakdown of supply-side primary interviews by company type, designation, and region: • By Company Type: Tier 1 (40%), Tier 2 (35%), and Tier 3 (25%) • By Designation: Directors (35%), Managers (40%), and Others (25%) • By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%) and Middle East Africa (5%) List of Companies Profiled in the Report o Certara USA. (US) o Siemens Healthineers (Germany) o GE Healthcare (US) o ConcertAI (US) o Medtronic (Ireland) o F. Hoffmann-La Roche Ltd (Switzerland) o Oracle(US) o NVIDIA Corporation(US) o Koninklijke Philips N.V. (Netherlands) o PathAI, Inc. (US) o CureMetrix, Inc. (US) o Mindpeak GmbH (Germany) o Paige AI, Inc. (US) o Predictive Oncology (US) o Exscientia (UK) o Insilico Medicine (US) o Iktos (Paris) o Tempus (US) o Azra AI (US) o CureMatch, Inc. (US) o OncoLens (US) o Triomics (US) o Clinakos. (US) o Perthera, Inc (US) o Cellworks Group, Inc. (US) o biomy, Inc. (Japan) Research Coverage This research report categorizes the AI in oncology market by player type [niche/point solution providers (including platform & service), integrated suite/platform providers (including platform & service), technology providers (only software), and business process service providers], by application [drug discovery {target identification & validation, lead identification & optimization, de novo drug design}, drug development {preclinical testing, predictive modeling for human trials, clinical trial optimization, adaptive trial design & monitoring}, diagnosis & early detection {imaging & radiology (mammography, computed tomography, magnetic resonance imaging (MRI), nuclear imaging (PET & SPECT), X-ray imaging, ultrasound, others), digital pathology & histopathology, liquid biopsy & biomarker detection, genetic risk prediction}, treatment planning & personalization {personalized treatment planning (precision medicine & genomic analysis, radiomics and radiogenomics, predictive models for treatment response, treatment recommendation systems), radiation therapy, chemotherapy, immunotherapy, targeted therapy (combination & dose optimization, AI-guided drug delivery), surgical planning & assistance (preoperative imaging and 3D modeling, intraoperative guidance and robotics, postoperative analysis & recovery)}, patient engagement & remote monitoring {symptom management & virtual assistance, remote patient monitoring, patient education & empowerment}, post-treatment surveillance & survivorship care {recurrence monitoring, long-term outcome prediction, mental health & support systems}, data management & analytics, other applications, by cancer type (solid tumors [including breast cancer lung cancer, prostate cancer, colorectal cancer, brain tumors, and other tumors], hematologic malignancies (including leukemia, lymphoma, multiple myeloma, other hematologic malignancies), by technology [machine learning {deep learning (convolutional neural networks (CNN), recurrent neural networks (RNN), generative adversarial networks (GAN), graph neural networks (GNN), others), supervised learning, reinforcement learning, unsupervised learning, other machine learning technologies}, natural language processing (NLP), context-aware processing and computing, computer vision, image analysis (including optical character recognition)], by deployment [on-premises model, cloud-based model, and hybrid model], by end user [healthcare providers {hospitals & clinics, specialty centers, laboratories & diagnostic centers, others}, pharmaceutical & biotechnology companies, medical device/equipment companies, academic & research institutions, government & regulatory agencies, healthcare payers, and others}, and region. The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the AI in oncology market. A thorough analysis of the key industry players has been done to provide insights into their business overview, offerings, and key strategies such as acquisitions, collaborations, partnerships, mergers, product/service launches & enhancements, and approvals in the AI in oncology market. Competitive analysis of upcoming startups in the AI in oncology market ecosystem is covered in this report. Reasons to Buy the Report The report will help market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall AI in oncology market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities. The report provides insights on the following pointers: • Analysis of key drivers (supportive regulations, growing necessity to reduce healthcare costs, reduction in costs and improved operational efficiency with AI in oncology platforms, rising demand for streamlined clinical trials, technological advancements in AI algorithms, rising cancer prevalence globally), restraints (ensuring data security is a major concern for both patients and users, elevated costs associated with adoption of AI, resistance to adoption), opportunities (focus on personalized treatment plans, collaborative efforts, AI-driven drug discovery), and challenges (limited availability of datasets, interoperability issues) influencing the growth of the AI in oncology market • Solution Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the AI in oncology market • Market Development: Comprehensive information about lucrative markets – the report analyses the AI in oncology market across varied regions. • Market Diversification: Exhaustive information about new solutions, untapped geographies, recent developments, and investments in the AI in oncology market • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Siemens Healthineers (Germany), GE Healthcare (US), ConcertAI (US), Medtronic (Ireland), F. Hoffmann-La Roche Ltd (Switzerland), Oracle(US), NVIDIA Corporation(US), Koninklijke Philips N.V. (Netherlands), PathAI, Inc. (US), CureMetrix, Inc. (US), Mindpeak GmbH (Germany), Paige AI, Inc. (US), Predictive Oncology (US), Exscientia (UK), and Insilico Medicine (US), among others in AI in oncology market.
目錄 Table of Contents
1 INTRODUCTION 46 1.1 STUDY OBJECTIVES 46 1.2 MARKET DEFINITION 46 1.3 STUDY SCOPE 47 1.3.1 MARKET SEGMENTATION AND GEOGRAPHIC SPREAD 47 1.3.2 INCLUSIONS AND EXCLUSIONS 48 1.3.3 YEARS CONSIDERED 51 1.4 CURRENCY CONSIDERED 51 1.5 STAKEHOLDERS 52 2 RESEARCH METHODOLOGY 53 2.1 RESEARCH DATA 53 2.1.1 SECONDARY DATA 54 2.1.1.1 Key data from secondary sources 55 2.1.2 PRIMARY DATA 55 2.1.2.1 Primary sources 56 2.1.2.1.1 Key data from primary sources 57 2.1.2.1.2 Key industry insights 58 2.1.2.2 Breakdown of primary interviews 58 2.2 MARKET ESTIMATION METHODOLOGY 59 2.3 MARKET SIZE ESTIMATION 60 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 68 2.5 RESEARCH ASSUMPTIONS 69 2.5.1 MARKET SIZING ASSUMPTIONS 69 2.5.2 OVERALL STUDY ASSUMPTIONS 69 2.6 RISK ASSESSMENT 70 2.7 RESEARCH LIMITATIONS 70 2.7.1 METHODOLOGY-RELATED LIMITATIONS 70 2.7.2 SCOPE-RELATED LIMITATIONS 70 3 EXECUTIVE SUMMARY 71 4 PREMIUM INSIGHTS 76 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS AI IN ONCOLOGY MARKET 76 4.2 AI IN ONCOLOGY MARKET, BY REGION 77 4.3 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL AND COUNTRY 77 4.4 AI IN ONCOLOGY MARKET, BY COUNTRY 78 4.5 AI IN ONCOLOGY MARKET: DEVELOPED MARKETS VS. EMERGING MARKETS 78 5 MARKET OVERVIEW 79 5.1 INTRODUCTION 79 5.2 MARKET DYNAMICS 79 5.2.1 DRIVERS 80 5.2.1.1 Increasing incidence of cancer disease 80 5.2.1.2 Growing need for early detection and diagnosis 80 5.2.1.3 Advancements in precision cancer treatment 81 5.2.1.4 Support from regulatory authorities 81 5.2.1.5 Increasing investments and funding 82 5.2.2 RESTRAINTS 83 5.2.2.1 High initial costs 83 5.2.2.2 Data integrity and algorithm validation 83 5.2.2.3 Integration with existing systems 83 5.2.3 OPPORTUNITIES 84 5.2.3.1 Radiomics and imaging analysis 84 5.2.3.2 Clinical trial optimization 86 5.2.3.3 Personalized treatment plans 86 5.2.3.4 Integration of multi-omics data 87 5.2.4 CHALLENGES 87 5.2.4.1 Limited availability of datasets 87 5.2.4.2 Data privacy and security 88 5.3 ECOSYSTEM ANALYSIS 89 5.4 CASE STUDY ANALYSIS 91 5.4.1 SIEMENS HEALTHINEERS IMPLEMENTED SYNGO.VIA RT IMAGE SUITE POWERED BY NVIDIA GPU-BASED SHERLOCK AI SUPERCOMPUTER 91 5.4.2 AI IN ONCOLOGY FOR PERSONALIZED TREATMENT PLANNING 91 5.4.3 PERSONALIZED OUTREACH FOR ONCOLOGISTS WITH TAKEDA'S AI SOLUTION 92 5.5 VALUE CHAIN ANALYSIS 93 5.6 PORTER'S FIVE FORCES ANALYSIS 95 5.6.1 BARGAINING POWER OF SUPPLIERS 96 5.6.2 BARGAINING POWER OF BUYERS 96 5.6.3 THREAT OF SUBSTITUTES 96 5.6.4 THREAT OF NEW ENTRANTS 97 5.6.5 INTENSITY OF COMPETITIVE RIVALRY 97 5.7 REGULATORY LANDSCAPE 97 5.7.1 NORTH AMERICA 97 5.7.2 EUROPE 98 5.7.3 ASIA PACIFIC 99 5.7.4 MIDDLE EAST & AFRICA 100 5.7.5 LATIN AMERICA 100 5.7.6 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100 5.8 PATENT ANALYSIS 103 5.8.1 PATENT PUBLICATION TRENDS FOR AI IN ONCOLOGY 103 5.8.2 JURISDICTION ANALYSIS 104 5.8.3 MAJOR PATENTS IN AI IN ONCOLOGY MARKET 105 5.9 TECHNOLOGY ANALYSIS 106 5.9.1 KEY TECHNOLOGIES 106 5.9.1.1 Machine learning 106 5.9.1.2 Natural language processing 106 5.9.1.3 Computer vision 106 5.9.2 COMPLEMENTARY TECHNOLOGIES 107 5.9.2.1 High-performance computing 107 5.9.2.2 Next-generation sequencing 107 5.9.2.3 Digital twins 107 5.9.2.4 Real-world evidence/real-world data 107 5.9.3 ADJACENT TECHNOLOGIES 107 5.9.3.1 Cloud computing 107 5.9.3.2 Theranostics 108 5.9.3.3 Augmented and virtual reality 108 5.10 INDUSTRY TRENDS 108 5.10.1 SHIFT TOWARD PERSONALIZED ONCOLOGY 108 5.10.2 EXPANSION OF AI-BASED CLINICAL TRIALS 108 5.11 PRICING ANALYSIS 109 5.11.1 INDICATIVE PRICING OF AI IN ONCOLOGY SOFTWARE, BY DEPLOYMENT MODEL 109 5.11.2 AVERAGE SELLING PRICE OF AI IN ONCOLOGY PLATFORMS, BY REGION (2023) 109 5.12 KEY CONFERENCES AND EVENTS, 2025 110 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 111 5.13.1 KEY STAKEHOLDERS 111 5.13.2 BUYING CRITERIA 112 5.14 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 113 5.15 END USER ANALYSIS 113 5.15.1 UNMET NEEDS 113 5.15.2 END USER EXPECTATIONS 114 5.16 INVESTMENT AND FUNDING SCENARIO 114 5.17 IMPACT OF GENERATIVE AI ON AI IN ONCOLOGY MARKET 115 5.17.1 KEY USE CASES 116 5.17.2 CASE STUDIES OF GENERATIVE AI IMPLEMENTATION 116 5.17.2.1 Case Study 1: Accelerated drug discovery with Generative AI and streamlined workflows 116   5.17.3 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 117 5.17.3.1 Pharmaceutical research and development market 117 5.17.3.2 Radiology and medical imaging market 117 5.17.3.3 Healthcare delivery systems market 118 5.17.4 USER READINESS AND IMPACT ASSESSMENT 118 5.17.4.1 User readiness 118 5.17.4.1.1 Use A: Healthcare providers 118 5.17.4.1.2 User B: Pharmaceutical & biotechnology companies 118 5.17.4.2 Impact assessment 118 5.17.4.2.1 User A: Healthcare providers 118 5.17.4.2.2 User B: Pharmaceutical & biotechnology companies 119 6 AI IN ONCOLOGY MARKET, BY TECHNOLOGY 120 6.1 INTRODUCTION 121 6.2 MACHINE LEARNING 121 6.2.1 DEEP LEARNING 124 6.2.1.1 Need to streamline clinical workflows, reduce delays, and improve patient outcomes to drive market 124 6.2.1.2 Convolutional neural networks 125 6.2.1.3 Recurrent neural networks 126 6.2.1.4 Generative adversarial networks 126 6.2.1.5 Graph neural networks 126 6.2.1.6 Others 126 6.2.2 SUPERVISED LEARNING 127 6.2.2.1 Surge in demand for accurate predictions and tailored treatments to drive market 127 6.2.3 REINFORCEMENT LEARNING 128 6.2.3.1 Extensive use in drug discovery to drive market 128 6.2.4 UNSUPERVISED LEARNING 129 6.2.4.1 Ability to perform complex tasks and uncover potential drug candidates to drive market 129 6.2.5 OTHER MACHINE LEARNING TECHNOLOGIES 130 6.3 NATURAL LANGUAGE PROCESSING 131 6.3.1 EMERGING DEVELOPMENTS IN ONCOLOGY CARE TO DRIVE MARKET 131 6.4 CONTEXT-AWARE PROCESSING AND COMPUTING 132 6.4.1 ABILITY TO OPTIMIZE CLINICAL WORKFLOWS TO DRIVE MARKET 132 6.5 COMPUTER VISION 133 6.5.1 ELEVATED DEMAND FOR PRECISION MEDICINE TO DRIVE MARKET 133 6.6 IMAGE ANALYSIS 134 6.6.1 AUTOMATION OF COMPLEX IMAGING TASKS TO DRIVE MARKET 134   7 AI IN ONCOLOGY MARKET, BY APPLICATION 136 7.1 INTRODUCTION 137 7.2 DRUG DISCOVERY 138 7.2.1 TARGET IDENTIFICATION & VALIDATION 139 7.2.1.1 Emphasis on avoiding last-stage failure in drug discovery to boost growth 139 7.2.2 HIT IDENTIFICATION & PRIORITIZATION 141 7.2.2.1 Need for large-scale data analysis in HTS screening to drive adoption 141 7.2.3 HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION 142 7.2.3.1 AI-driven lead generation to improve selectivity and binding mechanisms 142 7.2.4 LEAD OPTIMIZATION 143 7.2.4.1 Need to accelerate make-design-test cycles and high possibility of clinical drug failure to spur market 143 7.2.5 CANDIDATE SELECTION & VALIDATION 144 7.2.5.1 Candidate selection and validation to facilitate early drug discovery 144 7.3 DRUG DEVELOPMENT 145 7.3.1 PRECLINICAL TESTING 147 7.3.1.1 Need to identify risks and optimize candidates to boost growth 147 7.3.2 PREDICTIVE MODELING FOR HUMAN TRIALS 148 7.3.2.1 Need for leveraging AI for accurate dose selection and safety assessments to boost growth 148 7.3.3 CLINICAL TRIAL OPTIMIZATION 149 7.3.3.1 Need to enhance trial efficiency and outcomes with AI-driven insights to propel market 149 7.3.4 ADAPTIVE TRIAL DESIGN & MONITORING 150 7.3.4.1 AI-driven adaptive trial design & monitoring help improve flexibility and success rates 150 7.4 DIAGNOSIS & EARLY DETECTION 151 7.4.1 IMAGING & RADIOLOGY 152 7.4.1.1 Mammography 154 7.4.1.1.1 Need for accurate diagnosis of breast cancer to propel market 154 7.4.1.2 Computed tomography (CT) 154 7.4.1.2.1 Need for early diagnosis of solid tumors in lungs, liver, and brain to drive growth 154 7.4.1.3 Magnetic resonance imaging (MRI) 155 7.4.1.3.1 Need for optimizing imaging and enhancing tumor detection by integrating AI into MRI to propel demand 155 7.4.1.4 Nuclear imaging 156 7.4.1.4.1 Need for empowering AI-enhanced PET and SPECT imaging for precision oncology to drive growth 156 7.4.1.5 X-ray Imaging 157 7.4.1.5.1 Integrating AI-powered X-rays to automate detection of lung nodules to boost market 157 7.4.1.6 Ultrasound 158 7.4.1.6.1 Focus on integrating AI with ultrasound imaging to boost growth 158 7.4.1.7 Other imaging modalities 159 7.4.2 DIGITAL PATHOLOGY & HISTOPATHOLOGY 160 7.4.2.1 Focus on examining tissue samples to diagnose diseases to boost market 160 7.4.3 LIQUID BIOPSY & BIOMARKER DETECTION 161 7.4.3.1 Advancements in non-invasive diagnostic technologies to propel growth 161 7.4.4 GENETIC RISK PREDICTION 162 7.4.4.1 Increased awareness of people regarding hereditary cancer risk to encourage growth 162 7.5 TREATMENT PLANNING & PERSONALIZATION 163 7.5.1 PERSONALIZED TREATMENT PLANNING 164 7.5.1.1 Precision medicine & genomic analysis 166 7.5.1.1.1 Need for adopting personalized therapies to improve treatment response to boost growth 166 7.5.1.2 Radiomics & radiogenomics 167 7.5.1.2.1 Emphasis on optimizing radiomics and radiogenomics for disease characterization to propel demand 167 7.5.1.3 Predictive models for treatment response 168 7.5.1.3.1 Adoption of predictive modeling to analyze genetic information to improve growth 168 7.5.1.4 Treatment recommendation systems 168 7.5.1.4.1 Need for enhancing treatment decisions with data-driven insights to propel growth 168 7.5.2 RADIATION THERAPY 169 7.5.2.1 Need for effective tumor targeting to boost growth 169 7.5.3 CHEMOTHERAPY 170 7.5.3.1 Focus on optimizing chemotherapy for targeted treatment and risk prediction to boost segmental growth 170 7.5.4 IMMUNOTHERAPY 171 7.5.4.1 Use of immunotherapy for personalized and effective cancer care to boost growth 171 7.5.5 TARGETED THERAPY 172 7.5.5.1 Combination & dose optimization 173 7.5.5.1.1 Need for enhancing personalized dosing to augment segment growth 173 7.5.5.2 AI-guided drug delivery 174 7.5.5.2.1 Emphasis on achieving robust AI-powered drug delivery system to drive market 174 7.5.6 SURGICAL PLANNING & ASSISTANCE 175 7.5.6.1 Preoperative imaging & 3D modeling 176 7.5.6.1.1 AI-driven 3D models for enhanced oncology care 176   7.5.6.2 Intraoperative guidance and robotics 177 7.5.6.2.1 Focus on integrating robotic surgery to enhance precision in treatment to drive market 177 7.5.6.3 Postoperative analysis & recovery 178 7.5.6.3.1 Emphasis on enhancing AI in postoperative care to drive demand 178 7.6 PATIENT ENGAGEMENT & REMOTE MONITORING 179 7.6.1 SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE 180 7.6.1.1 Symptom management & virtual assistance tools are beneficial for chronic disease management 180 7.6.2 REMOTE PATIENT MONITORING 181 7.6.2.1 Need for AI-enhanced, real-time monitoring to augment growth 181 7.6.3 PATIENT EDUCATION & EMPOWERMENT 182 7.6.3.1 Improved health literacy and engagement with AI-curated insights 182 7.7 POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE 183 7.7.1 RECURRENCE MONITORING 184 7.7.1.1 Need to improve cancer surveillance and accurate recurrence detection and prognosis to drive market 184 7.7.2 LONG-TERM OUTCOME PREDICTION 186 7.7.2.1 Need for personalized care plans and chronic side-effect management to augment market 186 7.7.3 MENTAL HEALTH & SUPPORT SYSTEMS 187 7.7.3.1 Prioritizing mental health support in cancer care to augment segmental growth 187 7.8 DATA MANAGEMENT & ANALYTICS 188 7.8.1 INTEGRATION OF GENOMIC AND CLINICAL DATA TO ACCELERATE DEMAND FOR AI-POWERED ANALYTICS 188 7.9 OTHER APPLICATIONS 189 8 AI IN ONCOLOGY MARKET, BY CANCER TYPE 190 8.1 INTRODUCTION 191 8.2 SOLID TUMORS 191 8.2.1 RISING PREVALENCE OF SOLID TUMORS TO BOOST NEED FOR AI-DRIVEN INNOVATIONS 191 8.2.2 BREAST CANCER 193 8.2.3 LUNG CANCER 194 8.2.4 PROSTATE CANCER 195 8.2.5 COLORECTAL CANCER 196 8.2.6 BRAIN TUMOR 197 8.2.7 OTHER SOLID TUMORS 198 8.3 HEMATOLOGIC MALIGNANCIES 199 8.3.1 RISING CASES OF BLOOD CANCER TO DRIVE MARKET 199 8.3.2 LEUKEMIA 201 8.3.3 LYMPHOMA 202 8.3.4 MULTIPLE MYELOMA 203 8.3.5 OTHER HEMATOLOGIC MALIGNANCIES 204 8.4 OTHER CANCER TYPES 205 9 AI IN ONCOLOGY MARKET, BY END USER 206 9.1 INTRODUCTION 207 9.2 HEALTHCARE PROVIDERS 207 9.2.1 NEED FOR IMPROVED DIAGNOSTIC ACCURACY, PERSONALIZED TREATMENT PLANNING, AND ENHANCED WORKFLOW EFFICIENCY TO BOOST MARKET 207 9.2.2 HOSPITALS & CLINICS 209 9.2.3 SPECIALTY CENTERS 210 9.2.4 LABORATORIES & DIAGNOSTIC CENTERS 211 9.2.5 OTHER HEALTHCARE PROVIDERS 212 9.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 213 9.3.1 NEED TO LEVERAGE AI FOR ACCELERATED ONCOLOGY DRUG DISCOVERY AND CLINICAL TRIALS TO BOOST GROWTH 213 9.4 MEDICAL DEVICE/ EQUIPMENT COMPANIES 214 9.5 ACADEMIC & RESEARCH INSTITUTIONS 216 9.6 GOVERNMENT & REGULATORY AGENCIES 217 9.7 HEALTHCARE PAYERS 218 9.8 OTHER END USERS 219 10 AI IN ONCOLOGY MARKET, BY PLAYER TYPE 221 10.1 INTRODUCTION 222 10.2 NICHE/POINT SOLUTION PROVIDERS 222 10.2.1 NICHE/POINT SOLUTION PROVIDERS ACCELERATE CANCER DRUG DISCOVERY AND DEVELOPMENT 222 10.3 INTEGRATED SUITE/PLATFORM PROVIDERS 224 10.3.1 INTEGRATED SUITE/PLATFORM PROVIDERS REDUCE NEED FOR MULTIPLE VENDORS AND ACCELERATE WORKFLOWS 224 10.4 TECHNOLOGY PROVIDERS 225 10.4.1 DEMAND FOR IMPROVED ONCOLOGY WORKFLOWS TO DRIVE MARKET 225 10.5 BUSINESS PROCESS SERVICE PROVIDERS 227 10.5.1 FOCUS ON OPTIMIZING NON-CLINICAL ONCOLOGY WORKFLOWS TO PROPEL MARKET GROWTH 227 11 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL 228 11.1 INTRODUCTION 229 11.2 CLOUD-BASED MODEL 229 11.2.1 NEED FOR ADVANCED CANCER RESEARCH AND TREATMENT TO BOOST USE OF CLOUD-BASED AI PLATFORMS 229 11.3 ON-PREMISES MODEL 231 11.3.1 NEED FOR ENHANCED DATA SECURITY AND COMPLIANCE TO PROPEL ADOPTION OF ON-PREMISES MODEL 231 11.4 HYBRID MODEL 232 11.4.1 NEED FOR ENHANCING SCALABILITY AND DATA SECURITY IN DIAGNOSTICS TO DRIVE USE OF HYBRID-BASED AI PLATFORMS 232 12 AI IN ONCOLOGY MARKET, BY REGION 234 12.1 INTRODUCTION 235 12.2 NORTH AMERICA 236 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 239 12.2.2 US 249 12.2.2.1 Rising number of clinical trials and drug discovery to drive market 249 12.2.3 CANADA 260 12.2.3.1 Pharmaceutical giants advancing innovation and expanding access to clinical trials to fuel market 260 12.3 EUROPE 271 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 272 12.3.2 GERMANY 283 12.3.2.1 Advanced healthcare system and collaborative efforts to boost market 283 12.3.3 UK 293 12.3.3.1 Government support for developing new AI platforms to drive innovation 293 12.3.4 FRANCE 304 12.3.4.1 Growing R&D pipeline for oncology trials to drive market 304 12.3.5 ITALY 314 12.3.5.1 Favorable regulatory scenarios to propel AI adoption in oncology 314 12.3.6 SPAIN 325 12.3.6.1 Established network of research centers to propel market 325 12.3.7 REST OF EUROPE 336 12.4 ASIA PACIFIC 346 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 347 12.4.2 CHINA 359 12.4.2.1 Increasing healthcare expenditure to drive demand for oncology solutions 359 12.4.3 INDIA 369 12.4.3.1 Growing cancer burden and healthcare disparities to fuel adoption of AI in oncology 369 12.4.4 JAPAN 380 12.4.4.1 Aging population and rising cancer rates to drive growth 380 12.4.5 REST OF ASIA PACIFIC 390 12.5 LATIN AMERICA 401 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 402 12.5.2 BRAZIL 412 12.5.2.1 Rising cases of breast cancer to support market growth 412   12.5.3 MEXICO 422 12.5.3.1 Use of AI in pediatric cancer treatment and chemotherapy complications to fuel market growth 422 12.5.4 REST OF LATIN AMERICA 432 12.6 MIDDLE EAST & AFRICA 443 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 444 12.6.2 GCC COUNTRIES 454 12.6.2.1 Growing cancer cases and increasing clinical trials to drive growth 454 12.6.3 REST OF MIDDLE EAST & AFRICA 465 13 COMPETITIVE LANDSCAPE 476 13.1 INTRODUCTION 476 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 476 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 477 13.3 REVENUE ANALYSIS OF KEY PLAYERS 478 13.4 MARKET SHARE ANALYSIS 479 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 481 13.5.1 STARS 481 13.5.2 EMERGING LEADERS 481 13.5.3 PERVASIVE PLAYERS 481 13.5.4 PARTICIPANTS 481 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 483 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 488 13.6.1 PROGRESSIVE COMPANIES 488 13.6.2 RESPONSIVE COMPANIES 488 13.6.3 DYNAMIC COMPANIES 488 13.6.4 STARTING BLOCKS 488 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 490 13.7 COMPANY VALUATION AND FINANCIAL METRICS 492 13.8 BRAND/SOFTWARE COMPARISON 493 13.9 COMPETITIVE SCENARIO 493 13.9.1 PRODUCT LAUNCHES & ENHANCEMENTS 493 13.9.2 DEALS 494 13.9.3 EXPANSIONS 495 13.9.4 OTHER DEVELOPMENTS 495 14 COMPANY PROFILES 496 14.1 KEY PLAYERS 496 14.1.1 NVIDIA CORPORATION 496 14.1.1.1 Business overview 496 14.1.1.2 Products/Solutions offered 497   14.1.1.3 Recent developments 498 14.1.1.3.1 Deals 498 14.1.1.4 MnM view 498 14.1.1.4.1 Right to win 498 14.1.1.4.2 Strategic choices 499 14.1.1.4.3 Weaknesses and competitive threats 499 14.1.2 GE HEALTHCARE 500 14.1.2.1 Business overview 500 14.1.2.2 Products/Solutions offered 501 14.1.2.3 Recent developments 502 14.1.2.3.1 Product launches & approvals 502 14.1.2.3.2 Deals 502 14.1.2.4 MnM view 503 14.1.2.4.1 Right to win 503 14.1.2.4.2 Strategic choices 503 14.1.2.4.3 Weaknesses and competitive threats 503 14.1.3 SIEMENS HEALTHINEERS AG 504 14.1.3.1 Business overview 504 14.1.3.2 Products/Solutions offered 505 14.1.3.3 Recent developments 506 14.1.3.3.1 Product launches & approvals 506 14.1.3.3.2 Deals 506 14.1.3.3.3 Expansions 506 14.1.3.4 MnM view 507 14.1.3.4.1 Right to win 507 14.1.3.4.2 Strategic choices 507 14.1.3.4.3 Weaknesses and competitive threats 507 14.1.4 F. HOFFMANN-LA ROCHE LTD 508 14.1.4.1 Business overview 508 14.1.4.2 Products/Solutions offered 509 14.1.4.3 Recent developments 510 14.1.4.3.1 Product launches & approvals 510 14.1.4.3.2 Deals 510 14.1.4.4 MnM view 511 14.1.4.4.1 Right to win 511 14.1.4.4.2 Strategic choices 511 14.1.4.4.3 Weaknesses and competitive threats 511 14.1.5 INSILICO MEDICINE 512 14.1.5.1 Business overview 512 14.1.5.2 Products/Solutions offered 512 14.1.5.3 Recent developments 513   14.1.5.4 MnM view 520 14.1.5.4.1 Right to win 520 14.1.5.4.2 Strategic choices 520 14.1.5.4.3 Weaknesses and competitive threats 520 14.1.6 CONCERTAI 521 14.1.6.1 Business overview 521 14.1.6.2 Products/Solutions offered 521 14.1.6.3 Recent developments 522 14.1.6.3.1 Product launches & approvals 522 14.1.6.3.2 Deals 522 14.1.7 MEDTRONIC 523 14.1.7.1 Business overview 523 14.1.7.2 Products/Solutions offered 524 14.1.7.3 Recent developments 525 14.1.7.3.1 Product launches & approvals 525 14.1.7.3.2 Deals 525 14.1.8 ORACLE 526 14.1.8.1 Business overview 526 14.1.8.2 Products/Solutions offered 527 14.1.8.3 Recent developments 528 14.1.8.3.1 Product launches & approvals 528 14.1.8.3.2 Deals 528 14.1.9 KONINKLIJKE PHILIPS N.V. 529 14.1.9.1 Business overview 529 14.1.9.2 Products/Solutions offered 530 14.1.9.3 Recent developments 531 14.1.9.3.1 Deals 531 14.1.10 PREDICTIVE ONCOLOGY 532 14.1.10.1 Business overview 532 14.1.10.2 Products/Solutions offered 533 14.1.10.3 Recent developments 533 14.1.10.3.1 Product launches & approvals 533 14.1.10.3.2 Deals 533 14.1.11 EXSCIENTIA 534 14.1.11.1 Business overview 534 14.1.11.2 Products/Solutions offered 535 14.1.11.3 Recent developments 536 14.1.11.3.1 Product launches & approvals 536 14.1.11.3.2 Deals 536 14.1.11.3.3 Expansions 541 14.1.11.3.4 Other developments 542   14.1.12 PATHAI, INC. 543 14.1.12.1 Business overview 543 14.1.12.2 Products/Solutions offered 543 14.1.12.3 Recent developments 544 14.1.12.3.1 Product launches & approvals 544 14.1.12.3.2 Deals 544 14.1.13 CUREMETRIX, INC. 545 14.1.13.1 Business overview 545 14.1.13.2 Products/Solutions offered 545 14.1.13.3 Recent developments 545 14.1.13.3.1 Other developments 545 14.1.14 MINDPEAK GMBH 546 14.1.14.1 Business overview 546 14.1.14.2 Products/Solutions offered 546 14.1.14.3 Recent developments 547 14.1.14.3.1 Product launches & approvals 547 14.1.14.3.2 Deals 547 14.1.14.3.3 Other developments 547 14.1.15 PAIGE AI, INC. 548 14.1.15.1 Business overview 548 14.1.15.2 Products/Solutions offered 548 14.1.15.3 Recent developments 549 14.1.15.3.1 Product launches & approvals 549 14.1.15.3.2 Deals 549 14.1.15.3.3 Other developments 550 14.1.16 TEMPUS AI, INC. 551 14.1.16.1 Business overview 551 14.1.16.2 Products/Solutions offered 551 14.1.16.3 Recent developments 552 14.1.16.3.1 Product launches & approvals 552 14.1.16.3.2 Deals 553 14.1.16.3.3 Expansions 555 14.1.16.3.4 Other developments 556 14.1.17 IKTOS 557 14.1.17.1 Business overview 557 14.1.17.2 Products/Solutions offered 557 14.1.17.3 Recent developments 558 14.1.17.3.1 Deals 558 14.1.17.3.2 Other developments 561   14.2 OTHER PLAYERS 562 14.2.1 AZRA AI 562 14.2.2 CUREMATCH, INC. 563 14.2.3 ONCOLENS 563 14.2.4 TRIOMICS 564 14.2.5 CLINAKOS 565 14.2.6 PERTHERA, INC. 566 14.2.7 CELLWORKS GROUP, INC. 566 14.2.8 BIOMY, INC. 567 15 APPENDIX 568 15.1 DISCUSSION GUIDE 568 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 577 15.3 CUSTOMIZATION OPTIONS 579 15.4 RELATED REPORTS 579 15.5 AUTHOR DETAILS 580
圖表清單 List of Tables & Figures
TABLE 1 USD EXCHANGE RATES, 2021–2023 51 TABLE 2 FACTOR ANALYSIS 65 TABLE 3 AI IN ONCOLOGY MARKET: RISK ASSESSMENT 70 TABLE 4 AI IN ONCOLOGY MARKET: IMPACT ANALYSIS 85 TABLE 5 AI IN ONCOLOGY MARKET: ROLE OF COMPANIES IN ECOSYSTEM 90 TABLE 6 IMPACT OF PORTER’S FIVE FORCES ON AI IN ONCOLOGY MARKET 96 TABLE 7 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 100 TABLE 8 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 101 TABLE 9 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 TABLE 10 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102 TABLE 11 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 103 TABLE 12 JURISDICTION ANALYSIS OF TOP PATENT APPLICANT COUNTRIES FOR AI IN ONCOLOGY 104 TABLE 13 AI IN ONCOLOGY MARKET: AVERAGE SELLING PRICE, BY REGION, 2023 (USD THOUSAND) 110 TABLE 14 AI IN ONCOLOGY MARKET: KEY CONFERENCES AND EVENTS, 2025 110 TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS (%) 111 TABLE 16 KEY BUYING CRITERIA FOR TOP 3 END USERS 112 TABLE 17 UNMET NEEDS IN AI IN ONCOLOGY MARKET 113 TABLE 18 END USER EXPECTATIONS IN AI IN ONCOLOGY MARKET 114 TABLE 19 AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 121 TABLE 20 AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 123 TABLE 21 AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY REGION, 2022–2030 (USD MILLION) 124 TABLE 22 AI IN ONCOLOGY MARKET FOR DEEP LEARNING, BY REGION, 2022–2030 (USD MILLION) 127 TABLE 23 AI IN ONCOLOGY MARKET FOR SUPERVISED LEARNING, BY REGION, 2022–2030 (USD MILLION) 128 TABLE 24 AI IN ONCOLOGY MARKET FOR REINFORCEMENT LEARNING, BY REGION, 2022–2030 (USD MILLION) 129 TABLE 25 AI IN ONCOLOGY MARKET FOR UNSUPERVISED LEARNING, BY REGION, 2022–2030 (USD MILLION) 130 TABLE 26 AI IN ONCOLOGY MARKET FOR OTHER MACHINE LEARNING TECHNOLOGIES, BY REGION, 2022–2030 (USD MILLION) 131 TABLE 27 AI IN ONCOLOGY MARKET FOR NATURAL LANGUAGE PROCESSING, BY REGION, 2022–2030 (USD MILLION) 132 TABLE 28 AI IN ONCOLOGY MARKET FOR CONTEXT-AWARE PROCESSING AND COMPUTING, BY REGION, 2022–2030 (USD MILLION) 133 TABLE 29 AI IN ONCOLOGY MARKET FOR COMPUTER VISION, BY REGION, 2022–2030 (USD MILLION) 134 TABLE 30 AI IN ONCOLOGY MARKET FOR IMAGE ANALYSIS, BY REGION, 2022–2030 (USD MILLION) 135 TABLE 31 AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 137 TABLE 32 AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 138 TABLE 33 AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY REGION, 2022–2030 (USD MILLION) 139 TABLE 34 AI IN ONCOLOGY MARKET FOR TARGET IDENTIFICATION & VALIDATION, BY REGION, 2022–2030 (USD MILLION) 140 TABLE 35 AI IN ONCOLOGY MARKET FOR HIT IDENTIFICATION & PRIORITIZATION, BY REGION, 2022–2030 (USD MILLION) 141 TABLE 36 AI IN ONCOLOGY MARKET FOR HIT-TO-LEAD IDENTIFICATION/LEAD GENERATION, BY REGION, 2022–2030 (USD MILLION) 143 TABLE 37 AI IN ONCOLOGY MARKET FOR LEAD OPTIMIZATION, BY REGION, 2022–2030 (USD MILLION) 144 TABLE 38 AI IN ONCOLOGY MARKET FOR CANDIDATE SELECTION & VALIDATION, BY REGION, 2022–2030 (USD MILLION) 145 TABLE 39 AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 146 TABLE 40 AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY REGION, 2022–2030 (USD MILLION) 146 TABLE 41 AI IN ONCOLOGY MARKET FOR PRECLINICAL TESTING, BY REGION, 2022–2030 (USD MILLION) 147 TABLE 42 AI IN ONCOLOGY MARKET FOR PREDICTIVE MODELING FOR HUMAN TRIALS, BY REGION, 2022–2030 (USD MILLION) 148 TABLE 43 AI IN ONCOLOGY MARKET FOR CLINICAL TRIAL OPTIMIZATION, BY REGION, 2022–2030 (USD MILLION) 149 TABLE 44 AI IN ONCOLOGY MARKET FOR ADAPTIVE TRIAL DESIGN & MONITORING, BY REGION, 2022–2030 (USD MILLION) 150 TABLE 45 AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 151 TABLE 46 AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY REGION, 2022–2030 (USD MILLION) 152 TABLE 47 AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 153 TABLE 48 AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY REGION, 2022–2030 (USD MILLION) 153 TABLE 49 AI IN ONCOLOGY MARKET FOR MAMMOGRAPHY, BY REGION, 2022–2030 (USD MILLION) 154 TABLE 50 AI IN ONCOLOGY MARKET FOR COMPUTED TOMOGRAPHY, BY REGION, 2022–2030 (USD MILLION) 155 TABLE 51 AI IN ONCOLOGY MARKET FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2022–2030 (USD MILLION) 156 TABLE 52 AI IN ONCOLOGY MARKET FOR NUCLEAR IMAGING, BY REGION, 2022–2030 (USD MILLION) 157 TABLE 53 AI IN ONCOLOGY MARKET FOR X-RAY IMAGING, BY REGION, 2022–2030 (USD MILLION) 158 TABLE 54 AI IN ONCOLOGY MARKET FOR ULTRASOUND, BY REGION, 2022–2030 (USD MILLION) 159 TABLE 55 AI IN ONCOLOGY MARKET FOR OTHER IMAGING MODALITIES, BY REGION, 2022–2030 (USD MILLION) 159 TABLE 56 AI IN ONCOLOGY MARKET FOR DIGITAL PATHOLOGY & HISTOPATHOLOGY, BY REGION, 2022–2030 (USD MILLION) 160 TABLE 57 AI IN ONCOLOGY MARKET FOR LIQUID BIOPSY & BIOMARKER DETECTION, BY REGION, 2022–2030 (USD MILLION) 161 TABLE 58 AI IN ONCOLOGY MARKET FOR GENETIC RISK PREDICTION, BY REGION, 2022–2030 (USD MILLION) 162 TABLE 59 AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 163 TABLE 60 AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY REGION, 2022–2030 (USD MILLION) 164 TABLE 61 AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 165 TABLE 62 AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY REGION, 2022–2030 (USD MILLION) 165 TABLE 63 AI IN ONCOLOGY MARKET FOR PRECISION MEDICINE & GENOMIC ANALYSIS, BY REGION, 2022–2030 (USD MILLION) 166 TABLE 64 AI IN ONCOLOGY MARKET FOR RADIOMICS & RADIOGENOMICS, BY REGION, 2022–2030 (USD MILLION) 167 TABLE 65 AI IN ONCOLOGY MARKET FOR PREDICTIVE MODELS FOR TREATMENT RESPONSE, BY REGION, 2022–2030 (USD MILLION) 168 TABLE 66 AI IN ONCOLOGY MARKET FOR TREATMENT RECOMMENDATION SYSTEMS, BY REGION, 2022–2030 (USD MILLION) 169 TABLE 67 AI IN ONCOLOGY MARKET FOR RADIATION THERAPY, BY REGION, 2022–2030 (USD MILLION) 170 TABLE 68 AI IN ONCOLOGY MARKET FOR CHEMOTHERAPY, BY REGION, 2022–2030 (USD MILLION) 171 TABLE 69 AI IN ONCOLOGY MARKET FOR IMMUNOTHERAPY, BY REGION, 2022–2030 (USD MILLION) 172 TABLE 70 AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 172 TABLE 71 AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY REGION, 2022–2030 (USD MILLION) 173 TABLE 72 AI IN ONCOLOGY MARKET FOR COMBINATION & DOSE OPTIMIZATION, BY REGION, 2022–2030 (USD MILLION) 174 TABLE 73 AI IN ONCOLOGY MARKET FOR AI-GUIDED DRUG DELIVERY, BY REGION, 2022–2030 (USD MILLION) 175 TABLE 74 AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 176 TABLE 75 AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY REGION, 2022–2030 (USD MILLION) 176 TABLE 76 AI IN ONCOLOGY MARKET FOR PREOPERATIVE IMAGING & 3D MODELING, BY REGION, 2022–2030 (USD MILLION) 177 TABLE 77 AI IN ONCOLOGY MARKET FOR INTRAOPERATIVE GUIDANCE & ROBOTICS, BY REGION, 2022–2030 (USD MILLION) 178 TABLE 78 AI IN ONCOLOGY MARKET FOR POSTOPERATIVE ANALYSIS & RECOVERY, BY REGION, 2022–2030 (USD MILLION) 179 TABLE 79 AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 180 TABLE 80 AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY REGION, 2022–2030 (USD MILLION) 180 TABLE 81 AI IN ONCOLOGY MARKET FOR SYMPTOM MANAGEMENT & VIRTUAL ASSISTANCE, BY REGION, 2022–2030 (USD MILLION) 181 TABLE 82 AI IN ONCOLOGY MARKET FOR REMOTE PATIENT MONITORING, BY REGION, 2022–2030 (USD MILLION) 182 TABLE 83 AI IN ONCOLOGY MARKET FOR PATIENT EDUCATION & EMPOWERMENT, BY REGION, 2022–2030 (USD MILLION) 183 TABLE 84 AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 184 TABLE 85 AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY REGION, 2022–2030 (USD MILLION) 184 TABLE 86 AI IN ONCOLOGY MARKET FOR RECURRENCE MONITORING, BY REGION, 2022–2030 (USD MILLION) 185 TABLE 87 AI IN ONCOLOGY MARKET FOR LONG-TERM OUTCOME PREDICTION, BY REGION, 2022–2030 (USD MILLION) 186 TABLE 88 AI IN ONCOLOGY MARKET FOR MENTAL HEALTH & SUPPORT SYSTEMS, BY REGION, 2022–2030 (USD MILLION) 187 TABLE 89 AI IN ONCOLOGY MARKET FOR DATA MANAGEMENT & ANALYTICS, BY REGION, 2022–2030 (USD MILLION) 188 TABLE 90 AI IN ONCOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2030 (USD MILLION) 189 TABLE 91 AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 191 TABLE 92 AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 192 TABLE 93 AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY REGION, 2022–2030 (USD MILLION) 193 TABLE 94 AI IN ONCOLOGY MARKET FOR BREAST CANCER, BY REGION, 2022–2030 (USD MILLION) 194 TABLE 95 AI IN ONCOLOGY MARKET FOR LUNG CANCER, BY REGION, 2022–2030 (USD MILLION) 195 TABLE 96 AI IN ONCOLOGY MARKET FOR PROSTATE CANCER, BY REGION, 2022–2030 (USD MILLION) 196 TABLE 97 AI IN ONCOLOGY MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2030 (USD MILLION) 197 TABLE 98 AI IN ONCOLOGY MARKET FOR BRAIN TUMORS, BY REGION, 2022–2030 (USD MILLION) 198 TABLE 99 AI IN ONCOLOGY MARKET FOR OTHER SOLID TUMORS, BY REGION, 2022–2030 (USD MILLION) 199 TABLE 100 AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 200 TABLE 101 AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2022–2030 (USD MILLION) 201 TABLE 102 AI IN ONCOLOGY MARKET FOR LEUKEMIA, BY REGION, 2022–2030 (USD MILLION) 202 TABLE 103 AI IN ONCOLOGY MARKET FOR LYMPHOMA, BY REGION, 2022–2030 (USD MILLION) 203 TABLE 104 AI IN ONCOLOGY MARKET FOR MULTIPLE MYELOMA, BY REGION, 2022–2030 (USD MILLION) 204 TABLE 105 AI IN ONCOLOGY MARKET FOR OTHER HEMATOLOGICAL MALIGNANCIES, BY REGION, 2022–2030 (USD MILLION) 204 TABLE 106 AI IN ONCOLOGY MARKET FOR OTHER CANCER TYPES, BY REGION, 2022–2030 (USD MILLION) 205 TABLE 107 AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 207 TABLE 108 AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 208 TABLE 109 AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2022–2030 (USD MILLION) 209 TABLE 110 AI IN ONCOLOGY MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2030 (USD MILLION) 210 TABLE 111 AI IN ONCOLOGY MARKET FOR SPECIALTY CENTERS, BY REGION, 2022–2030 (USD MILLION) 211 TABLE 112 AI IN ONCOLOGY MARKET FOR LABORATORIES & DIAGNOSTIC CENTERS, BY REGION, 2022–2030 (USD MILLION) 212 TABLE 113 AI IN ONCOLOGY MARKET FOR OTHER HEALTHCARE PROVIDERS, BY REGION, 2022–2030 (USD MILLION) 212 TABLE 114 AI IN ONCOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2030 (USD MILLION) 214 TABLE 115 AI IN ONCOLOGY MARKET FOR MEDICAL DEVICE/ EQUIPMENT COMPANIES, BY REGION, 2022–2030 (USD MILLION) 215 TABLE 116 AI IN ONCOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2022–2030 (USD MILLION) 216 TABLE 117 AI IN ONCOLOGY MARKET FOR GOVERNMENT & REGULATORY AGENCIES, BY REGION, 2022–2030 (USD MILLION) 218 TABLE 118 AI IN ONCOLOGY MARKET FOR HEALTHCARE PAYERS, BY REGION, 2022–2030 (USD MILLION) 219 TABLE 119 AI IN ONCOLOGY MARKET FOR OTHER END USERS, BY REGION, 2022–2030 (USD MILLION) 220 TABLE 120 AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 222 TABLE 121 AI IN ONCOLOGY MARKET FOR NICHE/POINT SOLUTION PROVIDERS, BY REGION, 2022–2030 (USD MILLION) 223 TABLE 122 AI IN ONCOLOGY MARKET FOR INTEGRATED SUITE/PLATFORM PROVIDERS, BY REGION, 2022–2030 (USD MILLION) 225 TABLE 123 AI IN ONCOLOGY MARKET FOR TECHNOLOGY PROVIDERS, BY REGION, 2022–2030 (USD MILLION) 226 TABLE 124 AI IN ONCOLOGY MARKET FOR BUSINESS PROCESS SERVICE PROVIDERS, BY REGION, 2022–2030 (USD MILLION) 227 TABLE 125 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 229 TABLE 126 AI IN ONCOLOGY MARKET FOR CLOUD-BASED MODEL, BY REGION, 2022–2030 (USD MILLION) 231 TABLE 127 AI IN ONCOLOGY MARKET FOR ON-PREMISES MODEL, BY REGION, 2022–2030 (USD MILLION) 232 TABLE 128 AI IN ONCOLOGY MARKET FOR HYBRID MODEL, BY REGION, 2022–2030 (USD MILLION) 233 TABLE 129 AI IN ONCOLOGY MARKET, BY REGION, 2022–2030 (USD MILLION) 236 TABLE 130 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 239 TABLE 131 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 240 TABLE 132 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 240 TABLE 133 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 241 TABLE 134 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 241 TABLE 135 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 242 TABLE 136 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 242 TABLE 137 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 243 TABLE 138 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 243 TABLE 139 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 244 TABLE 140 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 244 TABLE 141 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 245 TABLE 142 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 245 TABLE 143 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 246 TABLE 144 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 246 TABLE 145 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 247 TABLE 146 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 247 TABLE 147 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 248 TABLE 148 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 248 TABLE 149 NORTH AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 249 TABLE 150 NORTH AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 249 TABLE 151 US: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 251 TABLE 152 US: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 251 TABLE 153 US: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 252 TABLE 154 US: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 252 TABLE 155 US: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 253 TABLE 156 US: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 253 TABLE 157 US: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 254 TABLE 158 US: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 254 TABLE 159 US: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 255 TABLE 160 US: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 255 TABLE 161 US: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 256 TABLE 162 US: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 256 TABLE 163 US: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 257 TABLE 164 US: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 257 TABLE 165 US: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 258 TABLE 166 US: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 258 TABLE 167 US: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 259 TABLE 168 US: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 259 TABLE 169 US: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 260 TABLE 170 US: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 260 TABLE 171 CANADA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 262 TABLE 172 CANADA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 262 TABLE 173 CANADA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 263 TABLE 174 CANADA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 263 TABLE 175 CANADA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 264 TABLE 176 CANADA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 264 TABLE 177 CANADA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 265 TABLE 178 CANADA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 265 TABLE 179 CANADA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 266 TABLE 180 CANADA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 266 TABLE 181 CANADA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 267 TABLE 182 CANADA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 267 TABLE 183 CANADA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 268 TABLE 184 CANADA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 268 TABLE 185 CANADA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 269 TABLE 186 CANADA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 269 TABLE 187 CANADA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 270 TABLE 188 CANADA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 270 TABLE 189 CANADA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 271 TABLE 190 CANADA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 271 TABLE 191 EUROPE: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 273 TABLE 192 EUROPE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 273 TABLE 193 EUROPE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 274 TABLE 194 EUROPE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 274 TABLE 195 EUROPE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 275 TABLE 196 EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 275 TABLE 197 EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 276 TABLE 198 EUROPE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 276 TABLE 199 EUROPE: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 277 TABLE 200 EUROPE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 277 TABLE 201 EUROPE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 278 TABLE 202 EUROPE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 278 TABLE 203 EUROPE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 279 TABLE 204 EUROPE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 279 TABLE 205 EUROPE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 280 TABLE 206 EUROPE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 280 TABLE 207 EUROPE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 281 TABLE 208 EUROPE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 281 TABLE 209 EUROPE: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 282 TABLE 210 EUROPE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 282 TABLE 211 EUROPE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 283 TABLE 212 GERMANY: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 284 TABLE 213 GERMANY: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 284 TABLE 214 GERMANY: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 285 TABLE 215 GERMANY: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 285 TABLE 216 GERMANY: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 286 TABLE 217 GERMANY: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 286 TABLE 218 GERMANY: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 287 TABLE 219 GERMANY: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 287 TABLE 220 GERMANY: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 288 TABLE 221 GERMANY: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 288 TABLE 222 GERMANY: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 289 TABLE 223 GERMANY: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 289 TABLE 224 GERMANY: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 290 TABLE 225 GERMANY: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 290 TABLE 226 GERMANY: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 291 TABLE 227 GERMANY: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 291 TABLE 228 GERMANY: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 292 TABLE 229 GERMANY: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 292 TABLE 230 GERMANY: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 293 TABLE 231 GERMANY: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 293 TABLE 232 UK: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 294 TABLE 233 UK: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 295 TABLE 234 UK: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 295 TABLE 235 UK: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 296 TABLE 236 UK: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 296 TABLE 237 UK: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 297 TABLE 238 UK: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 297 TABLE 239 UK: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 298 TABLE 240 UK: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 298 TABLE 241 UK: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 299 TABLE 242 UK: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 299 TABLE 243 UK: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 300 TABLE 244 UK: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 300 TABLE 245 UK: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 301 TABLE 246 UK: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 301 TABLE 247 UK: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 302 TABLE 248 UK: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 302 TABLE 249 UK: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 303 TABLE 250 UK: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 303 TABLE 251 UK: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 304 TABLE 252 FRANCE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 305 TABLE 253 FRANCE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 305 TABLE 254 FRANCE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 306 TABLE 255 FRANCE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 306 TABLE 256 FRANCE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 307 TABLE 257 FRANCE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 307 TABLE 258 FRANCE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 308 TABLE 259 FRANCE: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 308 TABLE 260 FRANCE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 309 TABLE 261 FRANCE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 309 TABLE 262 FRANCE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 310 TABLE 263 FRANCE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 310 TABLE 264 FRANCE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 311 TABLE 265 FRANCE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 311 TABLE 266 FRANCE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 312 TABLE 267 FRANCE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 312 TABLE 268 FRANCE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 313 TABLE 269 FRANCE: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 313 TABLE 270 FRANCE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 314 TABLE 271 FRANCE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 314 TABLE 272 ITALY: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 316 TABLE 273 ITALY: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 316 TABLE 274 ITALY: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 317 TABLE 275 ITALY: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 317 TABLE 276 ITALY: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 318 TABLE 277 ITALY: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 318 TABLE 278 ITALY: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 319 TABLE 279 ITALY: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 319 TABLE 280 ITALY: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 320 TABLE 281 ITALY: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 320 TABLE 282 ITALY: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 321 TABLE 283 ITALY: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 321 TABLE 284 ITALY: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 322 TABLE 285 ITALY: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 322 TABLE 286 ITALY: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 323 TABLE 287 ITALY: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 323 TABLE 288 ITALY: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 324 TABLE 289 ITALY: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 324 TABLE 290 ITALY: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 325 TABLE 291 ITALY: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 325 TABLE 292 SPAIN: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 326 TABLE 293 SPAIN: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 327 TABLE 294 SPAIN: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 327 TABLE 295 SPAIN: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 328 TABLE 296 SPAIN: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 328 TABLE 297 SPAIN: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 329 TABLE 298 SPAIN: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 329 TABLE 299 SPAIN: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 330 TABLE 300 SPAIN: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 330 TABLE 301 SPAIN: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 331 TABLE 302 SPAIN: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 331 TABLE 303 SPAIN: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 332 TABLE 304 SPAIN: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 332 TABLE 305 SPAIN: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 333 TABLE 306 SPAIN: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 333 TABLE 307 SPAIN: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 334 TABLE 308 SPAIN: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 334 TABLE 309 SPAIN: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 335 TABLE 310 SPAIN: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 335 TABLE 311 SPAIN: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 336 TABLE 312 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 337 TABLE 313 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 337 TABLE 314 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 338 TABLE 315 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 338 TABLE 316 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 339 TABLE 317 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 339 TABLE 318 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 340 TABLE 319 REST OF EUROPE AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 340 TABLE 320 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 341 TABLE 321 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 341 TABLE 322 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 342 TABLE 323 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 342 TABLE 324 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 343 TABLE 325 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 343 TABLE 326 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 344 TABLE 327 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 344 TABLE 328 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 345 TABLE 329 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 345 TABLE 330 REST OF EUROPE: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 346 TABLE 331 REST OF EUROPE: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 346 TABLE 332 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 349 TABLE 333 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 349 TABLE 334 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 350 TABLE 335 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 350 TABLE 336 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 351 TABLE 337 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 351 TABLE 338 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 352 TABLE 339 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 352 TABLE 340 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 353 TABLE 341 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 353 TABLE 342 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 354 TABLE 343 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 354 TABLE 344 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 355 TABLE 345 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 355 TABLE 346 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 356 TABLE 347 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 356 TABLE 348 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 357 TABLE 349 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 357 TABLE 350 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 358 TABLE 351 ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 358 TABLE 352 ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 359 TABLE 353 CHINA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 360 TABLE 354 CHINA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 360 TABLE 355 CHINA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 361 TABLE 356 CHINA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 361 TABLE 357 CHINA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 362 TABLE 358 CHINA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 362 TABLE 359 CHINA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 363 TABLE 360 CHINA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 363 TABLE 361 CHINA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 364 TABLE 362 CHINA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 364 TABLE 363 CHINA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 365 TABLE 364 CHINA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 365 TABLE 365 CHINA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 366 TABLE 366 CHINA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 366 TABLE 367 CHINA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 367 TABLE 368 CHINA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 367 TABLE 369 CHINA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 368 TABLE 370 CHINA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 368 TABLE 371 CHINA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 369 TABLE 372 CHINA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 369 TABLE 373 INDIA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 370 TABLE 374 INDIA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 371 TABLE 375 INDIA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 371 TABLE 376 INDIA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 372 TABLE 377 INDIA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 372 TABLE 378 INDIA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 373 TABLE 379 INDIA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 373 TABLE 380 INDIA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 374 TABLE 381 INDIA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 374 TABLE 382 INDIA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 375 TABLE 383 INDIA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 375 TABLE 384 INDIA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 376 TABLE 385 INDIA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 376 TABLE 386 INDIA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 377 TABLE 387 INDIA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 377 TABLE 388 INDIA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 378 TABLE 389 INDIA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 378 TABLE 390 INDIA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 379 TABLE 391 INDIA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 379 TABLE 392 INDIA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 380 TABLE 393 JAPAN: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 381 TABLE 394 JAPAN: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 381 TABLE 395 JAPAN: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 382 TABLE 396 JAPAN: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 382 TABLE 397 JAPAN: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 383 TABLE 398 JAPAN: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 383 TABLE 399 JAPAN: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 384 TABLE 400 JAPAN: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION)S 384 TABLE 401 JAPAN: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 385 TABLE 402 JAPAN: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 385 TABLE 403 JAPAN: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 386 TABLE 404 JAPAN: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 386 TABLE 405 JAPAN: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 387 TABLE 406 JAPAN: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 387 TABLE 407 JAPAN: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 388 TABLE 408 JAPAN: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 388 TABLE 409 JAPAN: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 389 TABLE 410 JAPAN: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 389 TABLE 411 JAPAN: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 390 TABLE 412 JAPAN: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 390 TABLE 413 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 391 TABLE 414 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 392 TABLE 415 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 392 TABLE 416 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 393 TABLE 417 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 393 TABLE 418 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 394 TABLE 419 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 394 TABLE 420 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 395 TABLE 421 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 395 TABLE 422 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 396 TABLE 423 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 396 TABLE 424 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 397 TABLE 425 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 397 TABLE 426 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 398 TABLE 427 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 398 TABLE 428 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 399 TABLE 429 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 399 TABLE 430 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 400 TABLE 431 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 400 TABLE 432 REST OF ASIA PACIFIC: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 401 TABLE 433 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 402 TABLE 434 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 403 TABLE 435 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 403 TABLE 436 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 404 TABLE 437 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 404 TABLE 438 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 405 TABLE 439 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 405 TABLE 440 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 406 TABLE 441 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 406 TABLE 442 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 407 TABLE 443 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 407 TABLE 444 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 408 TABLE 445 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 408 TABLE 446 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 409 TABLE 447 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 409 TABLE 448 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 410 TABLE 449 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 410 TABLE 450 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 411 TABLE 451 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 411 TABLE 452 LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 412 TABLE 453 LATIN AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 412 TABLE 454 BRAZIL: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 413 TABLE 455 BRAZIL: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 413 TABLE 456 BRAZIL: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 414 TABLE 457 BRAZIL: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 414 TABLE 458 BRAZIL: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 415 TABLE 459 BRAZIL: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 415 TABLE 460 BRAZIL: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 416 TABLE 461 BRAZIL: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 416 TABLE 462 BRAZIL: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 417 TABLE 463 BRAZIL: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 417 TABLE 464 BRAZIL: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 418 TABLE 465 BRAZIL: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 418 TABLE 466 BRAZIL: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 419 TABLE 467 BRAZIL: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 419 TABLE 468 BRAZIL: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 420 TABLE 469 BRAZIL: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 420 TABLE 470 BRAZIL: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 421 TABLE 471 BRAZIL: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 421 TABLE 472 BRAZIL: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 422 TABLE 473 BRAZIL: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 422 TABLE 474 MEXICO: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 423 TABLE 475 MEXICO: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 423 TABLE 476 MEXICO: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 424 TABLE 477 MEXICO: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 424 TABLE 478 MEXICO: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 425 TABLE 479 MEXICO: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 425 TABLE 480 MEXICO: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 426 TABLE 481 MEXICO: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 426 TABLE 482 MEXICO: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 427 TABLE 483 MEXICO: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 427 TABLE 484 MEXICO: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 428 TABLE 485 MEXICO: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 428 TABLE 486 MEXICO: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 429 TABLE 487 MEXICO: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 429 TABLE 488 MEXICO: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 430 TABLE 489 MEXICO: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 430 TABLE 490 MEXICO: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 431 TABLE 491 MEXICO: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 431 TABLE 492 MEXICO: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 432 TABLE 493 MEXICO: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 432 TABLE 494 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 433 TABLE 495 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 434 TABLE 496 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 434 TABLE 497 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 435 TABLE 498 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 435 TABLE 499 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 436 TABLE 500 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 436 TABLE 501 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 437 TABLE 502 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 437 TABLE 503 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 438 TABLE 504 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 438 TABLE 505 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 439 TABLE 506 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 439 TABLE 507 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 440 TABLE 508 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 440 TABLE 509 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 441 TABLE 510 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 441 TABLE 511 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 442 TABLE 512 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 442 TABLE 513 REST OF LATIN AMERICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 443 TABLE 514 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY COUNTRY, 2022–2030 (USD MILLION) 444 TABLE 515 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 445 TABLE 516 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 445 TABLE 517 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 446 TABLE 518 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 446 TABLE 519 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 447 TABLE 520 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 447 TABLE 521 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 448 TABLE 522 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 448 TABLE 523 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 449 TABLE 524 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 449 TABLE 525 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 450 TABLE 526 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 450 TABLE 527 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 451 TABLE 528 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 451 TABLE 529 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 452 TABLE 530 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 452 TABLE 531 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 453 TABLE 532 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 453 TABLE 533 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 454 TABLE 534 MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 454 TABLE 535 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 455 TABLE 536 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 456 TABLE 537 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 456 TABLE 538 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 457 TABLE 539 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 457 TABLE 540 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 458 TABLE 541 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 458 TABLE 542 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 459 TABLE 543 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 459 TABLE 544 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 460 TABLE 545 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 460 TABLE 546 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 461 TABLE 547 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 461 TABLE 548 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 462 TABLE 549 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 462 TABLE 550 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 463 TABLE 551 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 463 TABLE 552 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 464 TABLE 553 GCC COUNTRIES: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 464 TABLE 554 GCC COUNTRIES: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 465 TABLE 555 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY PLAYER TYPE, 2022–2030 (USD MILLION) 466 TABLE 556 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION) 466 TABLE 557 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR MACHINE LEARNING, BY TYPE, 2022–2030 (USD MILLION) 467 TABLE 558 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY APPLICATION, 2022–2030 (USD MILLION) 467 TABLE 559 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DISCOVERY, BY TYPE, 2022–2030 (USD MILLION) 468 TABLE 560 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DRUG DEVELOPMENT, BY TYPE, 2022–2030 (USD MILLION) 468 TABLE 561 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR DIAGNOSIS & EARLY DETECTION, BY TYPE, 2022–2030 (USD MILLION) 469 TABLE 562 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR IMAGING & RADIOLOGY, BY TYPE, 2022–2030 (USD MILLION) 469 TABLE 563 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TREATMENT PLANNING & PERSONALIZATION, BY TYPE, 2022–2030 (USD MILLION) 470 TABLE 564 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PERSONALIZED TREATMENT PLANNING, BY TYPE, 2022–2030 (USD MILLION) 470 TABLE 565 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR TARGETED THERAPY, BY TYPE, 2022–2030 (USD MILLION) 471 TABLE 566 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SURGICAL PLANNING & ASSISTANCE, BY TYPE, 2022–2030 (USD MILLION) 471 TABLE 567 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR PATIENT ENGAGEMENT & REMOTE MONITORING, BY TYPE, 2022–2030 (USD MILLION) 472 TABLE 568 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR POST-TREATMENT SURVEILLANCE & SURVIVORSHIP CARE, BY TYPE, 2022–2030 (USD MILLION) 472 TABLE 569 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY CANCER TYPE, 2022–2030 (USD MILLION) 473 TABLE 570 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR SOLID TUMORS, BY TYPE, 2022–2030 (USD MILLION) 473 TABLE 571 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022–2030 (USD MILLION) 474 TABLE 572 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY END USER, 2022–2030 (USD MILLION) 474 TABLE 573 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2022–2030 (USD MILLION) 475 TABLE 574 REST OF MIDDLE EAST & AFRICA: AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2022–2030 (USD MILLION) 475 TABLE 575 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 477 TABLE 576 AI IN ONCOLOGY MARKET: DEGREE OF COMPETITION 480 TABLE 577 AI IN ONCOLOGY MARKET: PLAYER TYPE FOOTPRINT 484 TABLE 578 AI IN ONCOLOGY MARKET: TECHNOLOGY FOOTPRINT 485 TABLE 579 AI IN ONCOLOGY MARKET: DEPLOYMENT MODEL FOOTPRINT 486 TABLE 580 AI IN ONCOLOGY MARKET: REGION FOOTPRINT 487 TABLE 581 AI IN ONCOLOGY MARKET: LIST OF KEY STARTUPS/SMES 490 TABLE 582 AI IN ONCOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES 491 TABLE 583 AI IN ONCOLOGY MARKET: PRODUCT LAUNCHES & ENHANCEMENTS, JANUARY 2021–NOVEMBER 2024 493 TABLE 584 AI IN ONCOLOGY MARKET: DEALS, JANUARY 2021–NOVEMBER 2024 494 TABLE 585 AI IN ONCOLOGY MARKET: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 495 TABLE 586 AI IN ONCOLOGY MARKET: OTHER DEVELOPMENTS, JANUARY 2021– NOVEMBER 2024 495 TABLE 587 NVIDIA CORPORATION: COMPANY OVERVIEW 496 TABLE 588 NVIDIA CORPORATION: PRODUCTS/SOLUTIONS OFFERED 497 TABLE 589 NVIDIA CORPORATION: DEALS, JANUARY 2021− NOVEMBER 2024 498 TABLE 590 GE HEALTHCARE: COMPANY OVERVIEW 500 TABLE 591 GE HEALTHCARE: PRODUCTS/SOLUTIONS OFFERED 501 TABLE 592 GE HEALTHCARE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024 502 TABLE 593 GE HEALTHCARE: DEALS, JANUARY 2021− NOVEMBER 2024 502 TABLE 594 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW 504 TABLE 595 SIEMENS HEALTHINEERS AG: PRODUCTS/SOLUTIONS OFFERED 505 TABLE 596 SIEMENS HEALTHINEERS AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024 506 TABLE 597 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021−NOVEMBER 2024 506 TABLE 598 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021−NOVEMBER 2024 506 TABLE 599 F. HOFFMANN-LA ROCHE LTD: COMPANY OVERVIEW 508 TABLE 600 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SOLUTIONS OFFERED 509 TABLE 601 F. HOFFMANN-LA ROCHE LTD: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024 510 TABLE 602 F. HOFFMANN-LA ROCHE LTD: DEALS, JANUARY 2021−NOVEMBER 2024 510 TABLE 603 INSILICO MEDICINE: COMPANY OVERVIEW 512 TABLE 604 INSILICO MEDICINE: PRODUCTS/SOLUTIONS OFFERED 512 TABLE 605 INSILICO MEDICINE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021– NOVEMBER 2024 513 TABLE 606 INSILICO MEDICINE: DEALS, JANUARY 2021–NOVEMBER 2024 514 TABLE 607 INSILICO MEDICINE: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024 519 TABLE 608 CONCERTAI: COMPANY OVERVIEW 521 TABLE 609 CONCERTAI: PRODUCTS/SOLUTIONS OFFERED 521 TABLE 610 CONCERTAI: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024 522 TABLE 611 CONCERTAI: DEALS, JANUARY 2021−NOVEMBER 2024 522 TABLE 612 MEDTRONIC: COMPANY OVERVIEW 523 TABLE 613 MEDTRONIC: PRODUCTS/SOLUTIONS OFFERED 524 TABLE 614 MEDTRONIC: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024 525 TABLE 615 MEDTRONIC: DEALS, JANUARY 2021−NOVEMBER 2024 525 TABLE 616 ORACLE: COMPANY OVERVIEW 526 TABLE 617 ORACLE: PRODUCTS/SOLUTIONS OFFERED 527 TABLE 618 ORACLE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024 528 TABLE 619 ORACLE: DEALS, JANUARY 2021−NOVEMBER 2024 528 TABLE 620 KONINKLIJKE PHILIPS N.V.: COMPANY OVERVIEW 529 TABLE 621 KONINKLIJKE PHILIPS N.V.: PRODUCTS/SOLUTIONS OFFERED 530 TABLE 622 KONINKLIJKE PHILIPS N.V.: DEALS, JANUARY 2021−NOVEMBER 2024 531 TABLE 623 PREDICTIVE ONCOLOGY: COMPANY OVERVIEW 532 TABLE 624 PREDICTIVE ONCOLOGY: PRODUCTS/SOLUTIONS OFFERED 533 TABLE 625 PREDICTIVE ONCOLOGY: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021−NOVEMBER 2024 533 TABLE 626 PREDICTIVE ONCOLOGY: DEALS, JANUARY 2021−NOVEMBER 2024 533 TABLE 627 EXSCIENTIA: COMPANY OVERVIEW 534 TABLE 628 EXSCIENTIA: PRODUCTS/SOLUTIONS OFFERED 535 TABLE 629 EXSCIENTIA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021– NOVEMBER 2024 536 TABLE 630 EXSCIENTIA: DEALS, JANUARY 2021–NOVEMBER 2024 536 TABLE 631 EXSCIENTIA: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 541 TABLE 632 EXSCIENTIA: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024 542 TABLE 633 PATHAI, INC.: COMPANY OVERVIEW 543 TABLE 634 PATHAI, INC.: PRODUCTS/SOLUTIONS OFFERED 543 TABLE 635 PATHAI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024 544 TABLE 636 PATHAI, INC.: DEALS, JANUARY 2021−NOVEMBER 2024 544 TABLE 637 CUREMETRIX, INC.: COMPANY OVERVIEW 545 TABLE 638 CUREMETRIX, INC.: PRODUCTS/SOLUTIONS OFFERED 545 TABLE 639 CUREMETRIX, INC.: OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024 545 TABLE 640 MINDPEAK GMBH: COMPANY OVERVIEW 546 TABLE 641 MINDPEAK GMBH: PRODUCTS/SOLUTIONS OFFERED 546 TABLE 642 MINDPEAK GMBH: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024 547 TABLE 643 MINDPEAK GMBH: DEALS, JANUARY 2021−NOVEMBER 2024 547 TABLE 644 MINDPEAK GMBH: OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024 547 TABLE 645 PAIGE AI, INC.: COMPANY OVERVIEW 548 TABLE 646 PAIGE AI, INC.: PRODUCTS/SOLUTIONS OFFERED 548 TABLE 647 PAIGE AI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021− NOVEMBER 2024 549 TABLE 648 PAIGE AI, INC.: DEALS, JANUARY 2021−NOVEMBER 2024 549 TABLE 649 PAIGE AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021−NOVEMBER 2024 550 TABLE 650 TEMPUS AI, INC.: COMPANY OVERVIEW 551 TABLE 651 TEMPUS AI, INC.: PRODUCTS/SOLUTIONS OFFERED 551 TABLE 652 TEMPUS AI, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021– NOVEMBER 2024 552 TABLE 653 TEMPUS AI, INC.: DEALS, JANUARY 2021–NOVEMBER 2024 553 TABLE 654 TEMPUS AI, INC.: EXPANSIONS, JANUARY 2021–NOVEMBER 2024 555 TABLE 655 TEMPUS AI, INC.: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024 556 TABLE 656 IKTOS: COMPANY OVERVIEW 557 TABLE 657 IKTOS: PRODUCTS/SOLUTIONS OFFERED 557 TABLE 658 IKTOS: DEALS, JANUARY 2021–NOVEMBER 2024 558 TABLE 659 IKTOS: OTHER DEVELOPMENTS, JANUARY 2021–NOVEMBER 2024 561 FIGURE 1 RESEARCH DESIGN 53 FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 58 FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 59 FIGURE 4 SUPPLY-SIDE MARKET ESTIMATION 61 FIGURE 5 AI IN ONCOLOGY MARKET: REVENUE ESTIMATION APPROACH 61 FIGURE 6 BOTTOM-UP APPROACH (2A): END USER SPENDING ON AI IN ONCOLOGY 63 FIGURE 7 BOTTOM-UP APPROACH (2B): END USER SPENDING ON AI IN ONCOLOGY 64 FIGURE 8 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2030) 66 FIGURE 9 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 67 FIGURE 10 TOP-DOWN APPROACH 67 FIGURE 11 DATA TRIANGULATION METHODOLOGY 68 FIGURE 12 INTEGRATED SUITE/PLATFORM PROVIDERS SEGMENT TO LEAD MARKET BY 2030 71 FIGURE 13 DIAGNOSIS & EARLY DETECTION SEGMENT TO ACCOUNT FOR LARGEST SHARE BY 2030 72 FIGURE 14 SOLID TUMORS SEGMENT TO LEAD MARKET BY 2030 72 FIGURE 15 AI IN ONCOLOGY MARKET, BY DEPLOYMENT MODEL, 2024 VS. 2030 (USD MILLION) 73 FIGURE 16 MACHINE LEARNING SEGMENT TO ACCOUNT FOR LARGEST SHARE BY 2030 73 FIGURE 17 HEALTHCARE PROVIDERS SEGMENT TO LEAD MARKET BY 2030 74 FIGURE 18 ASIA PACIFIC TO ACHIEVE HIGHEST GROWTH DURING FORECAST PERIOD 75 FIGURE 19 FOCUS ON COST-EFFECTIVE PROCESSES AND FAVORABLE GOVERNMENT SUPPORT AND FUNDING TO DRIVE MARKET 76 FIGURE 20 NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE DURING FORECAST PERIOD 77 FIGURE 21 CLOUD-BASED MODEL AND US ACCOUNTED FOR SIGNIFICANT SHARE IN 2023 77 FIGURE 22 INDIA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 78 FIGURE 23 GROWTH RATES OF EMERGING MARKETS TO BE HIGHER THAN THOSE OF DEVELOPED MARKETS DURING FORECAST PERIOD 78 FIGURE 24 AI IN ONCOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 79 FIGURE 25 NEW CANCER CASES AND CANCER DEATHS IN US, 2024 80 FIGURE 26 FUNDING RECEIVED BY AI IN ONCOLOGY COMPANIES IN 2024 82 FIGURE 27 NUMBER OF CANCER PUBLICATIONS OVER TIME (WITH OR WITHOUT AI AND RADIOMICS) 85 FIGURE 28 DISTRIBUTION OF CANCER CLINICAL TRIALS, BY PHASE 86 FIGURE 29 AI IN ONCOLOGY MARKET: ECOSYSTEM ANALYSIS 89 FIGURE 30 AI IN ONCOLOGY MARKET: VALUE CHAIN ANALYSIS 93 FIGURE 31 PORTER’S FIVE FORCES ANALYSIS OF AI IN ONCOLOGY MARKET 95 FIGURE 32 PATENT PUBLICATION TRENDS IN AI IN ONCOLOGY MARKET, 2015–2024 103 FIGURE 33 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR “AI IN ONCOLOGY” PATENTS (JANUARY 2015–SEPTEMBER 2024) 104 FIGURE 34 MAJOR PATENTS IN AI IN ONCOLOGY MARKET (JANUARY 2015– SEPTEMBER 2024) 105 FIGURE 35 AI IN ONCOLOGY MARKET: AVERAGE SELLING PRICE, BY REGION, 2023 110 FIGURE 36 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TOP 3 END USERS 111 FIGURE 37 KEY BUYING CRITERIA FOR TOP 3 END USERS 112 FIGURE 38 TRENDS AND DISRUPTIONS IMPACTING CUSTOMER BUSINESS 113 FIGURE 39 INVESTMENT AND FUNDING SCENARIO IN AI IN ONCOLOGY MARKET 114 FIGURE 40 POTENTIAL OF GENERATIVE AI IN AI IN ONCOLOGY MARKET 115 FIGURE 41 IMPACT OF GENERATIVE AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS 117 FIGURE 42 NEW CANCER CASES IN US, BY CANCER TYPE, 2024 192 FIGURE 43 PERCENTAGE ESTIMATION OF HEMATOLOGIC MALIGNANCY CASES IN US, BY TYPE, 2024 199 FIGURE 44 AI IN ONCOLOGY MARKET, BY REGION, 2023 (USD MILLION) 235 FIGURE 45 NORTH AMERICA: AI IN ONCOLOGY MARKET SNAPSHOT 238 FIGURE 46 DISTRIBUTION OF R&D COMPANIES, BY COUNTRY/REGION, 2021 VS. 2022 250 FIGURE 47 DISTRIBUTION OF CANCER CASES, BY CANCER TYPE, 2024 (MALES) 261 FIGURE 48 DISTRIBUTION OF CANCER CASES, BY CANCER TYPE, 2024 (FEMALES) 261 FIGURE 49 INCIDENCE OF CANCER IN MALES IN ITALY, BY CANCER TYPE, 2022 315 FIGURE 50 INCIDENCE OF CANCER IN FEMALES IN ITALY, BY CANCER TYPE, 2022 315 FIGURE 51 ASIA PACIFIC: AI IN ONCOLOGY MARKET SNAPSHOT 348 FIGURE 52 REVENUE ANALYSIS OF TOP 5 PLAYERS, 2019–2023 (USD BILLION) 478 FIGURE 53 AI IN ONCOLOGY MARKET SHARE ANALYSIS, 2023 479 FIGURE 54 AI IN ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023 482 FIGURE 55 AI IN ONCOLOGY MARKET: COMPANY FOOTPRINT 483 FIGURE 56 AI IN ONCOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023 489 FIGURE 57 COMPANY VALUATION OF KEY PLAYERS, 2024 492 FIGURE 58 EV/EBITDA OF KEY PLAYERS, 2024 492 FIGURE 59 AI IN ONCOLOGY MARKET: BRAND/PRODUCT COMPARISON 493 FIGURE 60 NVIDIA CORPORATION: COMPANY SNAPSHOT (2023) 497 FIGURE 61 GE HEALTHCARE: COMPANY SNAPSHOT (2023) 501 FIGURE 62 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2023) 505 FIGURE 63 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2023) 509 FIGURE 64 MEDTRONIC: COMPANY SNAPSHOT (2023) 524 FIGURE 65 ORACLE: COMPANY SNAPSHOT (2023) 527 FIGURE 66 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2023) 530 FIGURE 67 PREDICTIVE ONCOLOGY: COMPANY SNAPSHOT (2023) 532 FIGURE 68 EXSCIENTIA: COMPANY SNAPSHOT 535

同分類最新報告（醫療與生命科學）

查看醫療與生命科學全部報告 →

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們